References

Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ, Miller SS, Mulloy AL, Recker RR, Weiss SR, Heyden N, Musliner T, Suryawanshi S, Yates AJ, Lombardi A. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2000; 85: 720-6.

Davidson NE. Hormone-replacement therapy--breast versus heart versus bone. N Engl J Med 1995; 332: 1638-9.

De Leo V, Ditto A, la Marca A, Lanzetta D, Massafra C, Morgante G. Bone mineral density and biochemical markers of bone turnover in peri- and postmenopausal women. Calcif Tissue Int 2000; 66: 263-7.

Downs RW, Bell NH, Ettinger MP, Walsh BW, Favus MJ, Mako B, Wang L, Smith ME, Gormley GJ, Melton ME. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 2000: 85:1783-8

Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338: 736-46.

Hamanaka Y, Yamamoto I, Takada M, Matsushita R, Ota T, Yuh I, Morita R. Comparison of bone mineral density at various skeletal sites with quantitative ultrasound parameters of the calcaneus for assessment of vertebral fractures. J Bone Miner Metab 1999; 17: 195-200.

Ettinger B, Genant HK, Cann CE. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Intern Med 1987; 106: 40-5.

Feskanich D, Singh, V, Willett WC, Colditz GA. Vitamin A intake and hip fractures among postmenopausal women. JAMA 2002; 287: 47-54.

Gambert SR, Schultz BM, Hamdy RC. Osteoporosis: clinical features, prevention, and treatment. Endocrinol Metab Clin North Am 1995; 24: 317-71.

Gonnelli S, Cepollaro C, Pondrelli C, Martini S, Montagnini A, Monaco R, Gennari C. Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis. Calcif Tissue Int 1999; 65: 359-64.

Heikkinen AM, Parviainen M, Niskanen L, Komulainen M, Tuppurainen MT, Kroger H, Saarikoski S. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study. J Clin Endocrinol Metab 1997; 82: 2476-83.

Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280:605-13.

Jordan VC, Gapstur S, Morrow M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst 2001; 93:1449-57.

Khovidhunkit W, Shoback DM. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med 1999; 130:431-9.

Lindsay R, Cosman F, Lobo RA, Walsh BW, Harris ST, Reagan JE, Liss CL, Melton ME, Byrnes CA. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized controlled clinical trial. J Clin Endocrinol Metab 1999; 84:3076-81.

Lyritis GP, Ioannidis GV, Karachalios T, Roidis N, Kataxaki E, Papaioannou N, Kaloudis J, Galanos A. Analgesic effects of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized placebo-controlled clinical study. Clin J Pain 1999; 15: 284-9.

Malavolta N, Zanardi M, Veronesi M, Ripamonti C, Gnudi S. Calcitriol and alendronate combination in treatment of menopausal women with low bone mass. Int J Tissue React 1999; 21:51-9.

Marci CD, Viechnicki MB, Greenspan SL. Bone mineral densitometry substantially influences health-related behaviors of postmenopausal women. Calcif Tissue Int 2000 Feb; 66: 113-8.

McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, El Hajj Fuleihan G, Reda C, Yates AJ, Ravn P. Alendronate prevents postmenopausal bone loss in women without osteoporosis. Ann Intern Med 1998; 128: 253-61.

McClung MR, Geusens P, Miller PD, Zippel M, Bensen WG, Roux X, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333-40.

Melton LJ 3^rd, Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL. Relationship of bone turnover to bone density and fractures. J Bone Miner Res 1997; 12: 1083-91.

Meunier PJ, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S, Sarkar S, Liu T, Wong M, Draper MW. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Osteoporos Int 1999; 10: 330-6.

Miura H, Yamamoto I, Yuu I, Kigami Y, Ohta T, Yamamura Y, Ohnaka Y, Morita R. Estimation of bone mineral density and bone loss by means of bone metabolic markers in postmenopausal women. Endocr J 1995; 42: 797-802.

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41.

Raisz LG. The osteoporosis revolution. Ann Intern Med 1997; 126:458-62.

Recker RR, Davies M, Dowd RM, Heaney RP. The effect of low-dose continuous estrogen and progesterone therapy with calcium and Vitamin D on bone in elderly women. Ann Intern Med 1999; 130: 897-904.

Rubin CD, Pak CY, Adams-Huet B, Genant HK, Li J, Rao DS. Sustained-release sodium fluoride in the treatment of the elderly with established osteoporosis. Arch Intern Med 2001; 161: 2325-33.

Smith MR, McGovern FJ, Zietman ALL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 989-91.

The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the Post-menopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996; 276: 1389-96.

Tira MB, Noyan V, Yildiz A, Yildirim M, Daya S. Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study. Hum Reprod 2000: 15; 2087-92.

Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of non-vertebral fractures. JAMA 2001; 285: 2891-7.

Varenna M, Binelli L, Zucchi F, Ghiringhelli D, Sinigaglia L. Unbalanced diet to lower serum cholesterol is a risk factor for postmenopausal osteoporosis and distal forearm fracture. Osteoporos Int 2001; 12: 296-301.

van der Poest Clement E, Patka P, Vandormael K, Haarman H, Lips P. The effect of alendronate on bone mass after distal forearm fracture. J Bone Miner Res 2000; 15:586-93.

Content on Infoaging is constantly reviewed and updated by leading researchers specializing in the biology of aging and the diseases of aging. For a list of our content experts, click here.